Illumina has launched the Veracode ADME core panel, designed to help researchers study genetic predispositions for differential drug response and adverse events.
The Veracode ADME core panel is claimed to offer the most complete representation of the key biomarkers associated with drug absorption, distribution, metabolism and excretion (ADME) as standardised by pharmaceutical industry experts in the PharmADME core list.
Researchers using the product can analyse key ADME content in as little as one day, allowing studies to proceed faster and more efficiently.
Dan Masys, managing director of bioinformatics at Vanderbilt University, said: 'We selected the ADME core panel for its multiplex coverage of the key biomarkers associated with drugs in our initial study, and for its efficiency in processing samples.
'We are looking for a set of variants that reliably predict an adverse effect from a medication, and have more than 80,000 DNA samples with matches, de-identified medical records to support the study,' he added.
Masys is leading the Vanderbilt Electronic Systems for Pharmacogenetic Assessment study using the Veracode ADME Core Panel to generate an extensive pharmacogenetic database.
This database will be widely used to link genotypes to drug response phenotypes extracted from electronic health record data.
